Tower Research Capital LLC TRC Reduces Holdings in argenx SE (NASDAQ:ARGX)

Tower Research Capital LLC TRC reduced its holdings in shares of argenx SE (NASDAQ:ARGX) by 55.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 268 shares of the company’s stock after selling 338 shares during the period. Tower Research Capital LLC TRC’s holdings in argenx were worth $100,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. KB Financial Partners LLC grew its holdings in argenx by 112.5% during the first quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock valued at $27,000 after purchasing an additional 45 shares during the period. CI Investments Inc. raised its position in shares of argenx by 202.6% during the 4th quarter. CI Investments Inc. now owns 79 shares of the company’s stock valued at $30,000 after purchasing an additional 156 shares during the period. Captrust Financial Advisors increased its holdings in shares of argenx by 116.7% in the first quarter. Captrust Financial Advisors now owns 143 shares of the company’s stock worth $45,000 after purchasing an additional 77 shares during the last quarter. Fortis Capital Advisors LLC purchased a new stake in shares of argenx during the 4th quarter worth approximately $70,000. Finally, Rockefeller Capital Management L.P. increased its holdings in shares of argenx by 407.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 218 shares of the company’s stock worth $80,000 after buying an additional 175 shares during the last quarter. 52.77% of the stock is currently owned by institutional investors.

argenx Price Performance

Shares of ARGX stock opened at $514.77 on Monday. argenx SE has a 1-year low of $333.07 and a 1-year high of $550.76. The company has a market cap of $30.13 billion, a price-to-earnings ratio of -71.79 and a beta of 0.75. The stock has a 50 day simple moving average of $468.64 and a 200-day simple moving average of $412.34.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, July 27th. The company reported ($1.69) EPS for the quarter, hitting analysts’ consensus estimates of ($1.69). argenx had a negative net margin of 47.28% and a negative return on equity of 27.99%. The business had revenue of $281.16 million during the quarter, compared to analysts’ expectations of $258.32 million. During the same quarter in the previous year, the company earned ($3.81) earnings per share. Analysts anticipate that argenx SE will post -5.33 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the company. Robert W. Baird raised their price target on argenx from $460.00 to $566.00 in a research note on Tuesday, July 18th. Societe Generale began coverage on shares of argenx in a research report on Thursday, June 15th. They issued a “sell” rating for the company. UBS Group lowered shares of argenx from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $480.00 to $570.00 in a report on Monday, July 24th. Wedbush restated an “outperform” rating and set a $570.00 target price on shares of argenx in a report on Tuesday, July 18th. Finally, Wells Fargo & Company lifted their price target on argenx from $606.00 to $609.00 and gave the company an “overweight” rating in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, argenx presently has an average rating of “Moderate Buy” and an average target price of $522.73.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.